

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/522,130
(use as many sheets as necessary)		Filing Date	January 19, 2005
Sheet 1 of 2		First Named Inventor	Murray Goodman
		Group Art Unit	
		Examiner Name	
		Attorney Docket Number	SDUC1100J-1 (041673-3109)

Sheet

1

67

2

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	A1	WO	91/09958		Whitehead Institute for Biomedical Research	07-11-1991		
	A2	WO	94/04686		Biogen, Inc.	03-03-1994		
	A3	WO	98/52614		The Board of Trustees of the Leland Stanford Junior University	11-26-1998		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>	
	A4	BUSCHLE, M. et al., Transloading of tumor antigen-derived peptides into antigen-presenting cells. Proc. Natl. Acad. Sci. USA., 94, p. 3256-3261 (1997).		
	A5	EMI, N. et al., Gene Transfer Mediated by Polyarginine Requires a Formation of Big Carrier-Complex of DNA Aggregate, Biophys. Res. Commun., 231, p. 421-424 (1997).		
	A6	FEICHTINGER, L. et al., Triurethane-Protected Guanidines and Triflydiurethane-Protected Guanidines: New Reagents for Guanidinylation Reactions, J. Org. Chem., 63, p. 8432 (1998).		
	A7	LEONETTI, J. -P. et al., Biological Activity of Oligonucleotide-Poly(L-lysine) Conjugates: Mechanism of Cell Uptake, Bioconjugate Chem., 1, p. 149-153 (1990).		
	A8	MITCHELL, D.J. et al., Polyargine enters cells more efficiently than other polycationic homopolymers, J. Peptide Res., 55 p. 318-325 (2000).		
	A9	MURPHY, J.E. et al., A combinatorial approach to the discovery of efficient cationic peptoid reagents for gene delivery, Proc. Natl. Acad. Sci. USA., 95, p. 1517-1522 (1998).		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number Filing Date First Named Inventor Group Art Unit Examiner Name Attorney Docket Number	10/522,130 January 19, 2005 Murray Goodman   SDUC1100J-1 (041673-3109)
Sheet	2	of	2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	A10	PEPINSKY, R.B. et al., Specific Inhibition of a Human Papillomavirus E2 <i>Trans</i> -Activator by Intracellular Delivery of Its Repressor, DNA Cell Biol., 13, p. 1011-1019 (1994).	
	A11	RYSER, H.J.-P., A Membrane Effect of Basic Polymers dependent on Molecular Size, Nature (London), 215, p. 934-936 (1967).	
	A12	RYSER, N.J. -P. et al., Conjugation of methotrexate to poly(L-lysine) increases drug transport and overcomes drug resistance in cultured cells, Proc. Nat. Acad. Sci. USA., 75, p. 3867-3870 (1978).	
	A13	SCHWARZE, S.R. et al., In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the Mouse, Science, 285, p. 1569-1572 (1999).	
	A14	SHEN, W., et al., Conjugation of poly-L-lysine to albumin and horseradish peroxidase: A novel method of enhancing the cellular uptake of proteins, Proc. Nat. Acad. Sci. USA., 75, p. 1872-1876 (1978).	
	A15	VOCERO-AKBANI, A.M. et al., Killing HIV-infected cells by transduction with an HIV protease-activated caspase-3 protein, Nat. Med., 5, p. 29-33 (1999).	
	A16	WENDER, P.A. et al., The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: Peptoid molecular transporters, Proc. Natl. Acad. Sci. USA., 97, p. 13003-13008 (2000).	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.